Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABHD6 | Q9BV23 | 7/20 | 0.57 |
| ▸ | TRAP1 | Q12931 | 4/20 | 0.53 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.36 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.36 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.36 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20564523 | 0.85 | ABHD6 (0.60) | ABHD6TRAP1NOTUMAKR1C3CARM1 | |
| SCHEMBL1550147 | 0.85 | ABHD6 (0.60) | ABHD6TRAP1NOTUMAKR1C3CARM1 | |
| SCHEMBL31414516 | 0.80 | ABHD6 (0.52) | ABHD6TRAP1NOTUMCARM1PRMT6 | |
| SCHEMBL16101789 | 0.80 | ABHD6 (0.52) | ABHD6TRAP1NOTUM | |
| SCHEMBL16637906 | 0.80 | TRAP1 (0.43) | ABHD6TRAP1NOTUMAKR1C3HSP90AA1 | |
| SCHEMBL7946982 | 0.80 | TRAP1 (0.52) | ABHD6TRAP1NOTUMDPP8DPP9 | |
| SCHEMBL16269364 | 0.79 | AKR1C3 (0.42) | ABHD6TRAP1NOTUMAKR1C3HSP90AA1 | |
| SCHEMBL30772456 | 0.79 | TRAP1 (0.56) | ABHD6TRAP1NOTUMDPP8DPP9 | |
| SCHEMBL497487 | 0.79 | TRAP1 (0.56) | ABHD6TRAP1NOTUMDPP8DPP9 | |
| SCHEMBL3469584 | 0.79 | TRAP1 (0.53) | TRAP1NOTUMAKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023240024-A1 | SULFAMIDE DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20220411377-A1 | SELECTIVE NEURONAL NITRIC OXIDE SYNTHASE INHIBITORS | NORTHWESTERN UNIVERSITY | 2022-12-29 | — | — | US | disclosed |
| US-11053197-B2 | Carbazole derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-06 | — | — | US | disclosed |
| WO-2021081528-A1 | SELECTIVE NEURONAL NITRIC OXIDE SYNTHASE INHIBITORS | NORTHWESTERN UNIVERSITY (US) | 2021-04-29 | — | — | WO | disclosed |
| EP-3807270-A1 | NOVEL HETEROARYL HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2021-04-21 | — | — | EP | disclosed |
| US-20200255377-A1 | CARBAZOLE DERIVATIVES | Organization Name: BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-13 | — | — | US | disclosed |
| US-10676434-B2 | Carbazole derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-09 | — | — | US | disclosed |
| EP-3209651-B9 | CARBAZOLE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2020-05-20 | — | — | EP | disclosed |
| WO-2019238616-A1 | NOVEL HETEROARYL HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2019-12-19 | — | — | WO | disclosed |
| EP-3209651-B1 | CARBAZOLE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2019-10-23 | — | — | EP | disclosed |
| US-20170362176-A1 | CARBAZOLE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-12-21 | — | — | US | disclosed |
| EP-3209651-A1 | CARBAZOLE DERIVATIVES | Bristol-Myers Squibb Company (US) | 2017-08-30 | — | — | EP | disclosed |
| WO-2017040449-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-09 | — | — | WO | disclosed |
| EP-2773613-A1 | SUBSTITUTED BENZYLAMINE COMPOUNDS, THEIR USE IN MEDICINE, AND IN PARTICULAR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION | Astex Therapeutics Limited (GB) | 2014-09-10 | — | — | EP | disclosed |
| WO-2013064538-A1 | SUBSTITUTED BENZYLAMINE COMPOUNDS, THEIR USE IN MEDICINE, AND IN PARTICULAR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION | ASTEX THERAPEUTICS LIMITED (GB) | 2013-05-10 | — | — | WO | disclosed |
| US-7829665-B2 | Macrocyclic inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| EP-2125778-A1 | CERTAIN PYRAZOLINE DERIVATIVES WITH KINASE INHIBITORY ACTIVITY | Millennium Pharmaceuticals, Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20090148407-A1 | Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication | INTERMUNE, INC. (US) | 2009-06-11 | — | — | US | disclosed |
| WO-2008079277-A1 | CERTAIN PYRAZOLINE DERIVATIVES WITH KINASE INHIBITORY ACTIVITY | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| US-20070054842-A1 | Novel macrocyclic inhibitors of hepatitis C virus replication | ARRAY BIOPHARMA, INC. | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411377-A1 | SELECTIVE NEURONAL NITRIC OXIDE SYNTHASE INHIBITORS | NOS3, NOS1, NOS2 | ABHD6 2503/4885TRAP1 983/4885NOTUM 641/4885 |
| US-20070054842-A1 | Novel macrocyclic inhibitors of hepatitis C virus replication | EIF2AK2, HAVCR2, HCCS | ABHD6 3078/4885TRAP1 3893/4885NOTUM 3787/4885 |
| US-10676434-B2 | Carbazole derivatives | BTK, SYK, JAK2 | ABHD6 4173/4885TRAP1 3556/4885NOTUM 3710/4885 |
| US-20170362176-A1 | CARBAZOLE DERIVATIVES | BTK, SYK, JAK2 | ABHD6 4380/4885TRAP1 3136/4885NOTUM 3793/4885 |
| US-11053197-B2 | Carbazole derivatives | BTK, SYK, JAK2 | ABHD6 4173/4885TRAP1 3556/4885NOTUM 3710/4885 |
| US-20090148407-A1 | Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication | EIF2AK2, HAVCR2, HCCS | ABHD6 3264/4885TRAP1 4134/4885NOTUM 3531/4885 |
| US-20200255377-A1 | CARBAZOLE DERIVATIVES | BTK, SYK, JAK2 | ABHD6 4173/4885TRAP1 3556/4885NOTUM 3710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.